Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 2/3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Hypogonadism 1Fatigue Syndrome, Chronic 1Eunuchism 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × testosterone undecanoate × Clear all
NCT04049331 2026-04-22

Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Seattle Institute for Biomedical and Clinical Research

Phase 2 Active not recruiting
240 enrolled

Eunuchism, Hypogonadism, Fatigue Syndrome, Chronic

NCT05081193 2025-09-22

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

NCT03379012 2019-10-22

FARETES

Kidney Cancer Research Bureau

Phase 2 Completed
60 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡